Form 4: Denali Therapeutics Executive Exercises Stock Options and Acquires Shares

Alexander O. Schuth, COFO and Secretary of Denali Therapeutics, exercised stock options and acquired 6,708 shares of common stock on December 27, 2024.

Summary

• Alexander O. Schuth, the COFO and Secretary of Denali Therapeutics, executed a transaction involving the company's stock on December 27, 2024.
• Mr. Schuth exercised stock options to acquire 6,708 shares of common stock at a price of $5.28 per share.
• Following the transaction, Mr. Schuth directly owns 205,290 shares of common stock, which includes 118,810 unvested RSUs.
• He also indirectly owns 523,749 shares through The Schuth Family Trust.
• Additionally, Mr. Schuth holds 46,671 stock options.

Sentiment

Score: 6

Explanation: The document is a routine filing of an executive exercising stock options. It is neither particularly positive nor negative, but indicates the executive's continued involvement with the company.

Positives

• The exercise of stock options by a company executive can be seen as a positive sign of confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is typical for executives who receive stock options as part of their compensation package.
• The vesting schedule of the options, with 25% vesting initially and the remainder vesting monthly, is a common practice.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates the executive's confidence in the company.

Key Dates

Keywords

Denali Therapeutics, stock options, insider trading, executive compensation, share acquisition, DNLI, Form 4